1 Ocak 2021 Dergi makalesi Açık Erişim

Eskandari, Zahra; Bahadori, Fatemeh; Yenigun, Vildan Betul; Demiray, Mutlu; Eroglu, Mehmet Sayip; Kocyigit, Abdurrahim; Oner, Ebru Toksoy

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Eskandari, Zahra</dc:creator>
  <dc:creator>Bahadori, Fatemeh</dc:creator>
  <dc:creator>Yenigun, Vildan Betul</dc:creator>
  <dc:creator>Demiray, Mutlu</dc:creator>
  <dc:creator>Eroglu, Mehmet Sayip</dc:creator>
  <dc:creator>Kocyigit, Abdurrahim</dc:creator>
  <dc:creator>Oner, Ebru Toksoy</dc:creator>
  <dc:date>2021-01-01</dc:date>
  <dc:description>Chemoresistance (CR) is one of the reasons why chemotherapy agents like Gemcitabine (GMC) remain insufficient in healing breast cancer. Activation of Nuclear Factor-kappa B (NF-kappa B) during chemotherapy is known as an important factor in the development of CR. The hydrophobic polyphenol curcumin is shown to inhibit NF-kappa B and hence CR. The aim of this work was to increase the poor bioavailability of curcumin by loading it into the nano-micelles made of Poly (Lactide-co-Glycolide) (PLGA) and levan, where levan as a natural fructose homopolymer makes the nano-micelle more stable and increases its uptake using the fructose moieties. In this study, a PLGA-levan-curcumin formulation (PLC) was designed and characterized. The size was measured as 154.16 +/- 1.45 nm with a 67.68% encapsulation efficiency (EE%). The incorporation between the components was approved. Levan made the nano-micelles stable for at least three months, increased their uptake, and led to a 10,000-fold increase in the solubility of curcumin. The enhanced bioavailability of curcumin reduced the NF-kappa B levels elevated by GMC, both in vitro and in vivo. The PLC showed a complete tumor treatment, while GMC only showed a rate of 52%. These point to the great potential of the PLC to be used simultaneously with chemotherapy.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/229706</dc:identifier>
  <dc:identifier>oai:aperta.ulakbim.gov.tr:229706</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES 189 223-231</dc:source>
  <dc:title>Levan enhanced the NF-kappa B suppression activity of an oral nano PLGA-curcumin formulation in breast cancer treatment</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>